Vtyurin B M, Ivanov V N, Medvedev V S, Galantseva G F, Abdulkadyrov S A, Ivanova L F, Petrovskaya G A, Plichko V I
Int J Radiat Oncol Biol Phys. 1985 Mar;11(3):441-9. doi: 10.1016/0360-3016(85)90173-7.
A clinical study using 252Cf sources in brachytherapy of tumors began in the Research Institute of Medical Radiology of the Academy of Medical Sciences of the USSR in 1973. 252Cf afterloading cells were utilized by the method of simple afterloading. Dosimetry and radiation protection of medical personnel were developed. To substantiate optimal therapeutic doses of 252Cf neutrons, a correlation of dose, time, and treatment volume factors with clinical results of 252Cf interstitial implants in carcinoma of the tongue for 47 patients with a minimum follow-up period of 1 year was studied. Forty-nine interstitial implants have been performed. Seventeen patients received 252Cf implants alone (Group I), 17 other patients received 252Cf implants in combination with external radiation (Group II), and 15 patients were treated with interstitial implants for recurrent or residual tumors (Group III). Complete regression of carcinoma of the tongue was obtained in 48 patients (98%). Recurrences occurred in 1 patient (6%) in Group I, 6 patients (35%) in Group II, and 5 patients (33%) in Group III. Thirteen patients (27%) developed radiation necrosis. The therapeutic dose of neutron radiation from 252Cf sources in interstitial radiotherapy of primary tongue carcinomas (Group I) was found to be 7 to 9 Gy. Optimal therapeutic neutron dose in combined interstitial and external radiotherapy of primary tumors (Group II) was 5 to 6 Gy with an external radiation dose of 40 Gy. For recurrent and residual tumors (Group III), favorable results were obtained with tumor doses of 6.5 to 7 Gy.
1973年，苏联医学科学院医学放射学研究所开始了一项使用252Cf源进行肿瘤近距离治疗的临床研究。采用简单后装法使用252Cf后装单元。开展了医疗人员的剂量测定和辐射防护工作。为了证实252Cf中子的最佳治疗剂量，研究了47例舌癌患者（最短随访期为1年）252Cf组织间植入的剂量、时间和治疗体积因素与临床结果的相关性。共进行了49次组织间植入。17例患者仅接受252Cf植入（第一组），另外17例患者接受252Cf植入联合外照射（第二组），15例患者接受组织间植入治疗复发性或残留性肿瘤（第三组）。48例患者（98%）舌癌完全消退。第一组1例患者（6%）复发，第二组6例患者（35%）复发，第三组5例患者（33%）复发。13例患者（27%）发生放射性坏死。发现原发性舌癌组织间放疗（第一组）中252Cf源中子辐射的治疗剂量为7至9 Gy。原发性肿瘤组织间和外照射联合放疗（第二组）的最佳治疗中子剂量为5至6 Gy，外照射剂量为40 Gy。对于复发性和残留性肿瘤（第三组），肿瘤剂量为6.5至7 Gy时取得了良好效果。
